Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Glaucoma
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Glaucoma
    TopAbstracts in Glaucoma 08/25/2008 - (DGNews)
    TopAbstracts in Glaucoma 07/28/2008 - (DGNews)
    Sandoz Timolol Ophthalmic Solution Recalled Due to Potential Health Risk - (DGNews)
    TopAbstracts in Glaucoma 06/30/2008 - (DGNews)
    FDA Approves Triamcinolone Acetone Formulation for Ocular Use - (DGNews)

    News archive

     Recent webcasts/CME - Glaucoma
      Enhancing Adherence with Glaucoma Therapy: Practical Strategies for Superior Outcomes
      Glaucoma Progression: Detection and Management
      Managing Concomitant Eye Diseases: Expert Views on Glaucoma and Dry Eye
      Topics in Glaucoma Management: Systemic Effects of Medications
      Update on Glaucoma Treatment: ACT: Applying Trial Data on Fixed-Combination Therapy to Daily Clinical Practice

      Webcasts/CME archive

       Recent cases - Glaucoma
        Good Functional Recovery Following Intervention for Delayed Suprachoroidal Haemorrhage Post Bleb Needling: A Case Report
        Acute Bilateral Simultaneous Angle Closure Glaucoma After Topiramate Administration
        Topiramate-Induced Bilateral Angle-Closure Glaucoma
        Bilateral Acute Angle Closure Glaucoma as a Presentation of Isolated Microspherophakia in an Adult: Case Report
        Vascular Compression of the Optic Chiasm Resembling Glaucoma-Like Visual Field Defects

        Cases archive
          




        my personal edition > glaucoma > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        New Formulation of Allergan's Alphagan P Receives U.S. FDA Approval

        IRVINE, CA -- August 19, 2005 -- Allergan, Inc. today announced it has received approval from the U.S. Food and Drug Administration (FDA) to market AlphaganŽ P (brimonidine tartrate ophthalmic solution) 0.1%, indicated for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

        The new product is an optimized formulation of Alphagan (brimonidine tartrate ophthalmic solution) 0.2%, and was developed to further minimize drug exposure while maintaining the drug's favorable efficacy profile. This FDA approval is the latest advance in the Alphagan Franchise, which includes Alphagan P 0.15%, and currently reflects the third-largest selling glaucoma franchise in the world(1).

        "Our goal in developing Alphagan P 0.1% has been to ensure maximal efficacy of brimonidine with the least drug exposure possible," said Dr. Scott Whitcup, Allergan's Executive Vice President, Research & Development. "By improving bioavailability compared to the original Alphagan 0.2%, we have managed to decrease drug concentration by half without sacrificing efficacy. This milestone underscores Allergan's commitment to providing eye care specialists and patients with safe and efficacious medicines."

        In a clinical trial, Alphagan P ophthalmic solution 0.1% was proven to have IOP-lowering efficacy equivalent to Alphagan 0.2%, effectively lowering IOP in patients with open-angle glaucoma or ocular hypertension by approximately 2-6 mmHg. Alphagan P 0.1% is contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy. The most frequently reported adverse events included allergic conjunctivitis, conjunctival hyperemia and eye pruritus.


        SOURCE: Allergan, Inc.



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send